社区中阿尔茨海默病病理的流行
Dag Aarsland1,2, Anita Lenora Sunde3,4, Diego A Tovar-Rios5,6,7,8
1Centre for Age-Related Medicine (SESAM), Stavanger University Hospital, Stavanger, Norway. daarsland@gmail.com.
Nature
|December 17, 2025
概括
这种疾病
科学领域:
- 神经学
- 生物标志物
- 老年病学
背景情况:
- 阿尔茨海默病的神经病变 (ADNCs) 是认知障碍的主要原因,但其患病率尚未确立.
- 基于血液的生物标志物为评估ADNC提供了可扩展的方法.
- 化217 (p-tau217) 是ADNC的一个关键指标.
研究的目的:
- 使用血p-tau217估计挪威人群中ADNC的流行率.
- 确定老年人中阿尔茨海默病的临床前,前期和痴呆阶段的患病率.
- 评估ADNC与认知状态 (痴呆症,轻度认知障碍,认知正常) 之间的关联.
主要方法:
- 来自挪威人口队列的11,486个血样本的分析 (个体年龄大于57岁).
- 测量血p-tau217作为ADNCs的替代标记物.
- 跨认知状态的ADNC的年龄分层流行率估计和分析.
主要成果:
- 随着年龄的增长,ADNC的患病率从< 8% (58-69. 9岁) 增加到65. 2% (> 90岁).
- 在70岁以上的个体中,临床前AD: 10%,前期AD: 10. 4%,AD痴呆症: 9. 8%.
- 在70岁以上的患者中,发现有60%的痴呆症患者有ADNC,有32.6%的MCI患者有ADNC,有23.5%的MCI患者没有ADNC.
结论:
- 研究结果表明老年人患阿尔茨海默氏症痴呆的患病率高于此前的估计.
- 临床前阿尔茨海默病的发病率可能比以前估计的更低.
- 血p-tau217是人口研究中大规模ADNC评估的宝贵工具.
更多相关视频
08:29Symmetric Bihemispheric Postmortem Brain Cutting to Study Healthy and Pathological Brain Conditions in Humans
Published on: December 18, 2016
14.5K
09:38Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
Published on: November 14, 2017
15.5K
相关概念视频
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Alzheimer's Disease: Treatment
752
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
752
Dementia
486
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
486
Prevalence and Incidence
1.5K
In statistical epidemiology and health sciences, two essential metrics—prevalence and incidence—are fundamental for understanding disease dynamics within a population. These measures enable public health officials, epidemiologists, and researchers to assess the burden of diseases, allocate resources effectively, and design impactful public health policies and interventions.
Prevalence indicates the proportion of individuals in a population who have a specific disease or health...
Prevalence indicates the proportion of individuals in a population who have a specific disease or health...
1.5K
Parkinson's Disease: Overview
1.7K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.7K
